NEUARTIGE AMINOPYRIMIDINDERIVATE

European patent · EP3299368 · In force

Register entry

Publication number
EP3299368
Application number
EP17191467
Kind
European patent with effect for Switzerland and Liechtenstein
Status
In force
Specification
Granted
Filed
Nov 28, 2014
Published
Mar 28, 2018
Granted
Feb 26, 2020
Protection ends at the latest
Nov 27, 2034
Next annual fee due
Nov 30, 2026
IPC classes
C07D 403/12 (2006.01)
C07D 401/14 (2006.01)
C07D 401/10 (2006.01)
C07D 401/12 (2006.01)
C07D 405/12 (2006.01)
C07D 239/47 (2006.01)
A61P 29/00 (2006.01)
A61P 35/02 (2006.01)
A61K 31/505 (2006.01)
A61K 31/506 (2006.01)
Priority
EP 13195081 29.11.2013
Filing language
English
Source
Swissreg

Supplementary protection certificates

A certificate extends the patent’s protection for a medicine or a plant protection product authorised in Switzerland.

Remibrutinib

C03299368/01 · Medicine · Application · Protection from Nov 28, 2034 to Nov 27, 2039

Authorisation 70227 (Swissmedic, Jun 19, 2026)

History

What the Federal Institute of Intellectual Property published about this title, newest first.

  1. Dec 1, 2025

    Next annual fee due on

    Next annual fee due on
    30.11.2025 → 30.11.2026

    Published in Swissreg on 01.12.2025

  2. Dec 1, 2024

    Next annual fee due on

    Next annual fee due on
    30.11.2024 → 30.11.2025

    Published in Swissreg on 01.12.2024

  3. Dec 1, 2023

    Change

    Published in Swissreg on 01.12.2023

  4. Dec 1, 2022

    Change

    Published in Swissreg on 01.12.2022

  5. Feb 26, 2020

    Granted

    Published in Swissreg on 26.02.2020

Parties

Holder

Novartis AG

Lichtstrasse 35, 4056 Basel

Inventor

Angst, Daniela

4002 Basel

Vulpetti, Anna

4002 Basel

Gessier, François

4002 Basel

The register names each party by name and address. A holder or agent is linked to an organization where exactly one entity of the commercial register bears its name; the street of a party not so recognised is not shown here.